MUCINEX DM Drug Patent Profile

Which patents cover Mucinex Dm, and when can generic versions of Mucinex Dm launch?

Mucinex Dm is a drug marketed by Rb Hlth and is included in one NDA.

The generic ingredient in MUCINEX DM is dextromethorphan hydrobromide; guaifenesin. There are twenty-three drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the dextromethorphan hydrobromide; guaifenesin profile page.

Summary for MUCINEX DM

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	16
Drug Prices:	Drug price information for MUCINEX DM
Drug Sales Revenues:	Drug sales revenues for MUCINEX DM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MUCINEX DM
What excipients (inactive ingredients) are in MUCINEX DM?	MUCINEX DM excipients list
DailyMed Link:	MUCINEX DM at DailyMed

See drug prices for MUCINEX DM

See drug sales revenues for MUCINEX DM

Recent Clinical Trials for MUCINEX DM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vitaccess Ltd	Phase 4
American Health Research	Phase 4
Massachusetts Eye and Ear Infirmary	N/A

See all MUCINEX DM clinical trials

Pharmacology for MUCINEX DM

Drug Class	Expectorant Sigma-1 Agonist Uncompetitive N-methyl-D-aspartate Receptor Antagonist
Mechanism of Action	Sigma-1 Receptor Agonists Uncompetitive NMDA Receptor Antagonists
Physiological Effect	Decreased Respiratory Secretion Viscosity Increased Respiratory Secretions

Paragraph IV (Patent) Challenges for MUCINEX DM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MUCINEX DM	Extended-release Tablets	dextromethorphan hydrobromide; guaifenesin	600 mg/30 mg and 1200 mg/60 mg	021620	1	2008-12-17

US Patents and Regulatory Information for MUCINEX DM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-002	Apr 29, 2004		OTC	Yes	No
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-001	Apr 29, 2004		OTC	Yes	Yes

Expired US Patents for MUCINEX DM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-002	Apr 29, 2004
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-002	Apr 29, 2004
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-001	Apr 29, 2004
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-001	Apr 29, 2004
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-001	Apr 29, 2004
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-002	Apr 29, 2004

International Patents for MUCINEX DM

See the table below for patents covering MUCINEX DM around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	I359034
Cyprus	1108166
European Patent Office	1913937
Spain	2301537
Taiwan	I282285
Hong Kong	1052651
European Patent Office	1503739

Supplementary Protection Certificates for MUCINEX DM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1539166	2013/055	Ireland		PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
1539166	CR 2013 00059	Denmark		PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
1539166	2013C/064	Belgium		PRODUCT NAME: DEXTROMETHORPHANE OU UN SEL, PRCURSEUR DE DERIVE PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRURE DE DEXTROMETORPHANE ET EN PARTICULIER LE BROMHYDRURE DE DEXTROMETROPHANE MONHYDRATE ET QUINIDINE OU UN SEL,....; AUTHORISATION NUMBER AND DATE: EU/1/13/833 20130626
1539166	92323	Luxembourg		PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
1539166	SPC/GB13/070	United Kingdom		PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626
1539166	60/2013	Austria		PRODUCT NAME: KOMBINATION VON A) DEXTROMETHORPHAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE DEXTROMETHORPHANHYDROBROMID, UND INSBESONDERE DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT UND B) CHINIDIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE CHINIDINSULFAT, UND INSBESONDERE CHINIDINSULFATDIHYDRAT.; REGISTRATION NO/DATE: EU/1/13/833 20130626
1539166	13C0062	France		PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626

Market Dynamics and Financial Trajectory for Mucinex DM

Last updated: January 29, 2026

Executive Summary

Mucinex DM (dextromethorphan HBr and guaifenesin) is a leading over-the-counter (OTC) combination product primarily used to relieve cough and chest congestion. Market dynamics for Mucinex DM are influenced by factors such as rising prevalence of respiratory illnesses, evolving consumer preferences, regulatory classifications, and competition within the OTC drug sector. Financially, Mucinex DM has demonstrated consistent growth, driven by increased awareness, product line expansions, and strategic marketing initiatives. This report provides a comprehensive analysis of these factors, supported by quantitative data, market segmentation, competitive landscape, and forecasts.

---

1. Product Overview

Attribute	Details
Active Ingredients	Dextromethorphan HBr (antitussive), Guaifenesin (expectorant)
Therapeutic Area	Cough suppression, chest congestion relief
Formulation	Tablets, liquids, multi-symptom relief formulations
Regulatory Status	OTC in US, classified as general consumer health product

---

2. Market Dynamics

2.1. Industry Overview

The global cough and cold remedy market was valued at approximately USD 7.3 billion in 2021, with a compound annual growth rate (CAGR) projected at 4.8% over 2022-2027 [1]. The US OTC segment accounts for roughly 45-50% of this market, with Mucinex DM holding a significant share.

2.2. Key Drivers

Drivers	Impact
Rising Incidence of Respiratory Conditions	Increased demand due to flu, COVID-19, allergies
Consumer Preference for OTC Accessibility	Shift towards self-medication reduces reliance on prescriptions
Aging Population	Older demographics prone to chronic cough and congestion
Product Innovation	Extended-release formulations, multi-symptom formulations

2.3. Market Challenges

Challenges	Impact
Regulatory Constraints	Classification as OTC limits certain claims, affects marketing
Competition	Intense rivalry with brands like Robitussin, DayQuil, Sudafed
Generic Competition	Loss of exclusivity undermines pricing power
Consumer Attachment to Natural/Herbal Alternatives	Influences purchasing trends

2.4. Consumer Behavior and Trends

• Preference for multi-symptom relief medications.
• Increased online accessibility and purchasing of OTC products.
• Growing awareness of medication safety and side effects.
• Preference for convenient packaging (e.g., small bottles, multi-dose formats).

2.5. Regulatory Environment

• In the US, regulated by the FDA’s OTC monograph system.
• Dextromethorphan faces scrutiny due to misuse potential; regulations around sales age restrictions have been implemented [2].
• Emerging markets are adopting stricter OTC guidelines, influencing global sales trajectories.

---

3. Market Segmentation

Segment	Description	Market Share (Estimate)
By Distribution Channel	Pharmacies, e-commerce, grocery stores	~60% pharmacy, 25% e-commerce, 15% grocery
By Geography	North America, Europe, Asia-Pacific	North America: 70%, Europe: 20%, Asia-Pacific: 10%
By Demographics	Adults (18-64), Seniors (>65), Pediatrics	Adults: 65%, Seniors: 25%, Pediatrics: 10%

---

4. Competitive Landscape

Major Players	Market Share	Key Strategies	Product Portfolio
Reckitt Benckiser (Mucinex)	~45%	Brand loyalty, Multi-channel marketing, Innovation	Mucinex DM, Multi-symptom formulas
Johnson & Johnson	~25%	Diversified OTC portfolio	Sudafed, Tylenol, Robitussin
Pfizer	~15%	Strategic alliances, Patent strategies	Robitussin, Theraflu
Other Competitors	~15%	Price competition, Natural brands	Various generics, herbal OTCs

4.1. Mucinex DM’s Positioning and Strategy

• Focus on multi-symptom relief.
• Extensive advertising campaigns targeting adult consumers.
• Product line extension: Mucinex D (with decongestant), Mucinex Sinus-Max.
• Expansion into online sales channels.

---

5. Financial Trajectory

Year	Estimated Revenue (USD)	Growth Rate	Notes
2020	$800 million	—	Pre-pandemic baseline
2021	$850 million	+6.25%	Pandemic influence — increased respiratory issues
2022	$900 million	+5.9%	Continued growth, new variants in marketing
2023	$950 million	+5.6%	Expanded distribution, younger demographics
2024*	$1.0 billion	+5.3%	Forecasted, driven by market penetration

*Projection assumes consistent market growth and successful product innovations.

5.1. Revenue Drivers

• Increased respiratory illness prevalence post-COVID-19.
• Consumer shift towards convenient OTC therapies.
• Product line expansions and packaging innovations.

5.2. Cost and Profitability Factors

Factor	Impact
R&D Expenses	Moderate, mainly for formulation updates
Marketing	Significant, especially in digital channels
Manufacturing	Economies of scale reduce unit costs
Regulatory Compliance	Ongoing, impacts timelines and costs

5.3. Margin Analysis

Metric	2021	2022	Projected 2024
Gross Margin	~50%	52%	55%
Operating Margin	~20%	22%	24%
Net Margin	~15%	17%	19%

---

6. Comparative Analysis With Competitors

Parameter	Mucinex DM	Robitussin	DayQuil/NyQuil	Sudafed
Active Ingredients	Dextromethorphan + Guaifenesin	Guaifenesin + DM or Pseudoephedrine	Acetaminophen + Dextromethorphan + Phenylephrine	Pseudoephedrine

| Market Share (US OTC cough/ cold segment) | ~15-20% | ~10-15% | ~10% | ~5-10% | | Price Range | USD 8-12 | USD 7-10 | USD 10-15 | USD 8-12 | | Innovation Focus | Multi-symptom, extended release | Herbal variants | Combo with pain relief | Decongestants, combo packs |

7. Future Outlook and Opportunities

7.1. Market Growth Prospects

• Predicted CAGR of 4-6% over the next five years.
• Emerging markets (e.g., China, India) are experiencing rapid OTC segment expansion.
• Increased focus on respiratory health due to climate change, pollution, and pandemics.

7.2. Product Development and Innovation Opportunities

• Digital integration: smart packaging, telemedicine collaborations.
• Natural and herbal formulations as alternatives.
• Controlled-release formulations to improve compliance.
• Expanding into pediatric and geriatric segments with tailored formulations.

7.3. Regulatory and Policy Trends

• Stringent regulations on dextromethorphan sale age restrictions (e.g., Canada, UK).
• Moving toward digital OTC sales regulation.
• Increasing emphasis on safety and misuse prevention.

---

8. Key Takeaways

• Mucinex DM maintains a strong market position driven by high consumer demand for OTC cough and cold remedies.
• Market dynamics hinge on the rising burden of respiratory illnesses, aging demographics, and product innovation.
• Competitive rivalry is intense; continuous brand differentiation and innovation are essential.
• Revenues are projected to grow at a CAGR of approximately 5% through 2024, bolstered by market expansion into emerging regions.
• Regulatory considerations, especially regarding safety and misuse of active ingredients, influence market strategies.

---

9. FAQs

Q1: What factors are most influencing the growth of Mucinex DM?
The primary growth drivers include increased respiratory illness prevalence, consumer preference for OTC self-medication, demographic shifts favoring older populations, and product line expansions.

Q2: How does regulatory policy impact Mucinex DM market prospects?
Regulations around ingredients like dextromethorphan can affect sales volume and marketing strategies, especially restrictions on sales age and misuse controls.

Q3: What are the main competitive threats to Mucinex DM?
Intense competition from generics, herbal alternatives, and other multi-symptom OTC formulations pose threats. Additionally, the entry of new formulations targeting natural health trends influences market share.

Q4: How significant is online sales growth for Mucinex DM?
Online sales have grown substantially, accounting for approximately 25-30% of OTC cough/cold product sales, offering opportunities for targeted marketing and direct consumer engagement.

Q5: What are the major opportunities for expanding Mucinex DM’s market share?
Expanding into emerging markets, innovating with natural and extended-release formulations, enhancing digital presence, and developing targeted marketing campaigns are key opportunities.

---

References

[1] Global Industry Analysts Inc., "Cough and Cold Remedies Market Forecast," 2022.
[2] U.S. Food and Drug Administration, "Dextromethorphan and Abuse Potential," 2021.